NASDAQ · SLN
Healthcare · Biotechnology
$12.50
Up+$0.25 (+1.98%)
Updated Sep 17, 2026, 4:27 PM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SLN closed at $12.50 after 20 trading sessions, down 8.16% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $12.53 | $12.775 | $12.241 | $12.50 | 983.81K |
| Sep 15, 2026 | $13.11 | $13.11 | $12.10 | $12.46 | 1.38M |
| Sep 14, 2026 | $12.95 | $13.28 | $12.72 | $13.06 | 1.1M |
| Sep 11, 2026 | $13.32 | $13.42 | $12.881 | $13.02 | 685.91K |
| Sep 10, 2026 | $13.38 | $13.81 | $13.04 | $13.31 | 682.63K |
| Sep 9, 2026 | $13.60 | $14.00 | $13.36 | $13.55 | 645.88K |
| Sep 8, 2026 | $14.24 | $14.47 | $13.40 | $13.69 | 1.35M |
| Sep 4, 2026 | $14.63 | $14.79 | $14.42 | $14.59 | 611.15K |
| Sep 3, 2026 | $14.85 | $15.09 | $14.445 | $14.79 | 572.41K |
| Sep 2, 2026 | $14.70 | $15.28 | $14.10 | $14.79 | 634.2K |
| Sep 1, 2026 | $13.49 | $14.89 | $13.26 | $14.74 | 1.13M |
| Aug 31, 2026 | $13.39 | $13.6499 | $13.0896 | $13.53 | 478.19K |
| Aug 28, 2026 | $13.46 | $13.685 | $13.18 | $13.42 | 539.7K |
| Aug 27, 2026 | $13.47 | $13.685 | $13.36 | $13.45 | 283.67K |
| Aug 26, 2026 | $13.68 | $13.68 | $13.355 | $13.53 | 301.7K |
| Aug 25, 2026 | $13.31 | $13.99 | $13.31 | $13.67 | 645.03K |
| Aug 24, 2026 | $13.37 | $13.59 | $13.05 | $13.29 | 723.69K |
| Aug 21, 2026 | $13.17 | $13.48 | $13.13 | $13.27 | 740.55K |
| Aug 20, 2026 | $13.50 | $13.5699 | $13.01 | $13.17 | 585.26K |
| Aug 19, 2026 | $14.59 | $14.59 | $13.47 | $13.61 | 977.26K |
The latest Smart Investors Daily articles mentioning SLN.
SLN research
Company profile and research snapshot.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
SeekingAlpha · Sep 16, 2026
Silence Therapeutics plc (SLN) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 8:30 AM EDTCompany ParticipantsSteven Romano -...
Benzinga · Sep 8, 2026
U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
Yahoo · Sep 2, 2026
LONDON, September 02, 2026--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in the following conferences and invited investors to participate by webcast.
Benzinga · Aug 11, 2026
Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and raises the price target from $25 to $32.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SLN.
